Agape Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.40 M
as on 09-07-2024
- Paid Up Capital ₹ 0.40 M
as on 09-07-2024
- Company Age 14 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 10.00 M
as on 09-07-2024
- Revenue %
(FY 2022)
- Profit -5.08%
(FY 2022)
- Ebitda 79.66%
(FY 2022)
- Net Worth -1.13%
(FY 2022)
- Total Assets -0.21%
(FY 2022)
About Agape Lifesciences
The Corporate was formerly known as Pearl Lifesciences Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.40 M and a paid-up capital of Rs 0.40 M.
The company has closed loans amounting to ₹1.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Shanmugasundaram Madhavan and Gayathrimadhavan serve as directors at the Company.
- CIN/LLPIN
U33112TN2010PTC074116
- Company No.
074116
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jan 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Agape Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shanmugasundaram Madhavan  | Director | 01-Jul-2013 | Current |
| Gayathrimadhavan | Director | 01-Jan-2010 | Current |
Financial Performance and Corporate Structure Insights of Agape Lifesciences.
Agape Lifesciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 5.08% decrease in profit. The company's net worth dipped by a decrease of 1.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Agape Lifesciences?
In 2021, Agape Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Healthway India Private Limited
Active 11 years 5 monthsShanmugasundaram Madhavan and Gayathrimadhavan are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 13 Jul 2010 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Agape Lifesciences?
Unlock and access historical data on people associated with Agape Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agape Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agape Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
